PTC Therapeutics, Inc. $PTCT Shares Purchased by Comerica Bank

Key Points

• Comerica Bank dramatically increased its stake in PTC Therapeutics, boosting its holdings by 3,231.9% to 17,426 shares worth about $1.32 million in the fourth quarter.
• PTC Therapeutics reported better-than-expected quarterly results, with EPS of -$0.03 versus estimates of -$0.45 and revenue of $272.6 million versus $217.4 million expected, while revenue rose 43.5% year over year.
• The company also raised its FY 2026 revenue guidance to $1.1 billion-$1.2 billion, and analysts remain broadly constructive with a consensus rating of Moderate Buy and an average price target of $88.36.

Comerica Bank boosted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3,231.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,426 shares of the biopharmaceutical company's stock after purchasing an additional 16,903 shares during the period. Comerica Bank's holdings in PTC Therapeutics were worth $1,324,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its stake in shares of PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 236 shares during the period. Optiver Holding B.V. raised its position in shares of PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 249 shares during the period. Salomon & Ludwin LLC acquired a new position in PTC Therapeutics in the fourth quarter valued at approximately $41,000. IFP Advisors Inc lifted its holdings in PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 310 shares during the last quarter. Finally, First Horizon Corp purchased a new position in PTC Therapeutics in the fourth quarter worth approximately $53,000.

PTC Therapeutics Stock Up 14.3%

NASDAQ:PTCT opened at $73.69 on Friday. The stock's fifty day moving average is $67.69 and its two-hundred day moving average is $72.07. PTC Therapeutics, Inc. has a 52 week low of $43.17 and a 52 week high of $87.50. The stock has a market capitalization of $6.11 billion, a price-to-earnings ratio of -31.63 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.42. The business had revenue of $272.55 million during the quarter, compared to analyst estimates of $217.42 million. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The company's quarterly revenue was up 43.5% on a year-over-year basis. During the same period last year, the business posted $10.04 earnings per share. On average, sell-side analysts expect that PTC Therapeutics, Inc. will post -1.1 EPS for the current fiscal year.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, EVP Lee Scott Golden sold 10,000 shares of PTC Therapeutics stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $63.38, for a total value of $633,800.00. Following the completion of the transaction, the executive vice president directly owned 79,944 shares of the company's stock, valued at $5,066,850.72. The trade was a 11.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Mark Elliott Boulding sold 3,081 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total transaction of $213,698.16. Following the sale, the vice president owned 108,231 shares in the company, valued at $7,506,902.16. This trade represents a 2.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 126,492 shares of company stock worth $8,634,621 over the last ninety days. Company insiders own 5.50% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on PTCT shares. Truist Financial raised PTC Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. Cantor Fitzgerald reiterated an "overweight" rating on shares of PTC Therapeutics in a report on Friday, February 20th. Jefferies Financial Group downgraded PTC Therapeutics from a "buy" rating to a "hold" rating and cut their price objective for the stock from $91.00 to $76.00 in a research report on Monday, March 30th. Barclays restated an "overweight" rating and issued a $120.00 price objective on shares of PTC Therapeutics in a report on Monday, February 23rd. Finally, Wall Street Zen cut shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $88.36.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.